The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel

This publication has 82 references indexed in Scilit:

• Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2004
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
  The Lancet, 2004
• Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
  Arthritis & Rheumatism, 2003
• Guidelines for the management of rheumatoid arthritis: 2002 Update
  Arthritis & Rheumatism, 2002
• Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
  The Lancet, 1999
• Etanercept Therapy in Rheumatoid Arthritis
  Annals of Internal Medicine, 1999
• A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
  New England Journal of Medicine, 1999
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
  Arthritis & Rheumatism, 1998
• The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
  Cell, 1994